UK markets closed
NIKKEI 225
29,663.50+697.49(+2.41%)HANG SENG
29,452.57+472.36(+1.63%)CRUDE OIL
60.16-0.48(-0.79%)
CureVac N.V. (CVAC)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
96.18+1.88 (+1.99%)
At close: 4:00PM EST
96.80 +0.62 (0.64%)
After hours: 5:56PM EST
| Previous close | 94.30 |
| Open | 95.50 |
| Bid | 96.00 x 1100 |
| Ask | 96.99 x 1300 |
| Day's range | 94.99 - 97.00 |
| 52-week range | 36.15 - 151.80 |
| Volume | 740,758 |
| Avg. volume | 789,088 |
| Market cap | 17.977B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 87.52 |
- Motley Fool
The Johnson & Johnson Vaccine Has Competition in the Race to Treat New Strains
You might have thought the coronavirus vaccine race ended when Pfizer (NYSE: PFE) crossed the finish line first in December. Variants from Brazil, the U.K., and South Africa worry the scientific community (and the rest of us) the most at the moment. Johnson & Johnson (NYSE: JNJ) highlighted exactly how its investigational vaccine performed against those new strains in its phase 3 trial.
- Yahoo Finance UK
UK orders 50 million CureVac vaccines to fight mutant COVID-19 strains
If approved, the 50 million doses will be on top of the 407 million vaccine doses already secured by the government to date.
- Yahoo Finance UK
GlaxoSmithKline partners with CureVac to develop vaccines for new COVID-19 variants
The development programme will begin immediately, with the target of introducing the vaccine in 2022, subject to regulatory approval.
© 2021 Verizon Media. All rights reserved.
